Phase I-II study of escalating doses of amifostine combined with high-dose cyclophosphamide

Abstract

Amifostine can be given safely at a dose of 910 mg/m2 four times in 1 day in combination with HD-CTX. With this schedule amifostine did not show a myeloprotective effect.

A Prospective Study of Salivary Gland Function in Lymphoma Patients Receiving Head and Neck Irradiation

“…The use of amifostine for cytoprotection has been investigated in the lymphoma population in the setting of systemic therapy but not radiation therapy to the head and neck (20)(21)(22)(23). Although our patient numbers are too small to establish amifostine's effectiveness as a radioprotector against xerostomia, the drug appeared to be well tolerated without significant toxicity associated with hypotension.…”

Protective Effect of Lycium ruthenicum Murr. Against Radiation Injury in Mice

“…Amifostine (WR-2721), developed the by U.S. Army Research Institute, can significantly protect normal cells and reduce apoptosis after radiation therapy, and it is the only cytoprotective agent approved by the Food and Drug Administration (FDA) specifically for use as a radioprophylactic [ 1 , 2 ]. However, low blood pressure, nausea, vomiting and other adverse reactions have still restricted its broad use [ 3 , 4 , 5 ]. Therefore, the search for anti-radiation drugs is one of the most important tasks, which could have a positive effect on patients after radiation therapy.…”